Advertisement
Advertisement
TVTX
Travere Therapeutics, Inc. Common Stock
65.67
USDSponsored
-1.85
-2.74%
Aug 28, 15:59 UTC -4
Closed
Pre-Market
65.80
+0.13
+0.20%
TVTX Earnings Reports
Positive Surprise Ratio
TVTX beat 18 of 43 last estimates.
42%
Next Report
Date of Next Report
Oct 28, 2026
Estimate for Q3 26 (Revenue/ EPS)
$198.49M
/-$0.01
Implied change from Q2 26 (Revenue/ EPS)
+17.04%
/-116.67%
Implied change from Q3 25 (Revenue/ EPS)
+20.40%
/-103.57%
Travere Therapeutics, Inc. Common Stock earnings per share and revenue
On Aug 04, 2026, TVTX reported earnings of 0.06 USD per share (EPS) for Q2 26, beating the estimate of -0.14 USD, resulting in a 142.40% surprise. Revenue reached 169.58 million, compared to an expected 162.78 million, with a 4.18% difference. The market reacted with a +12.03% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 11 analysts forecast an EPS of -0.01 USD, with revenue projected to reach 198.49 million USD, implying an decrease of -116.67% EPS, and increase of 17.04% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Alvotech Ordinary Shares
Report Date
Aug 19, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.11
Surprise
-300.00%
Immatics N.V. Ordinary Shares
Report Date
Aug 18, 2026 For Q2 26
Estimate
-$0.43
Actual
-$0.46
Surprise
-5.70%
Prenetics Global Limited Class A Ordinary Share
Report Date
Aug 18, 2026 For Q2 26
Estimate
-$0.71
Actual
-$0.53
Surprise
+26.30%
Clinuvel Pharmaceuticals Limited - ADR
Report Date
Aug 27, 2026 For Q4 26
Estimate
$0.50
Actual
-Surprise
-
Anavex Life Sciences
Report Date
Aug 25, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+1.96%
Molecular Partners AG - ADR
Report Date
Aug 25, 2026 For Q2 26
Estimate
-Actual
-$0.35
Surprise
-
Chemomab Therapeutics Ltd. - ADR
Report Date
Aug 19, 2026 For Q2 26
Estimate
-$0.15
Actual
-$0.24
Surprise
-56.86%
EVOGENE LTD.
Report Date
Aug 18, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.14
Surprise
+49.16%
FAQ
What were Travere Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Travere Therapeutics, Inc. Common Stock reported EPS of $0.06, beating estimates by 142.4%, and revenue of $169.58M, 4.18% above expectations.
How did the market react to Travere Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 12.03%, changed from $56.02 before the earnings release to $62.76 the day after.
When is Travere Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Oct 28, 2026.
What are the forecasts for Travere Therapeutics, Inc. Common Stock's next earnings report?
Based on 11
analysts, Travere Therapeutics, Inc. Common Stock is expected to report EPS of -$0.01 and revenue of $198.49M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement